{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:21:42Z","timestamp":1789924902413,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T00:00:00Z","timestamp":1352073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We investigated serum brain\u2010derived neurotrophin factor (BDNF), nerve growth factor (NGF), neurotrophin\u20103 (NTF3), neurotrophin\u20104 (NTF4) and the glial\u2010derived neurotrophic factor (GDNF), in relation to ketamine efficacy, in bipolar depressed patients resistant to treatment with antidepressants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010five patients (4 male, 21 female), aged 27\u201367\u2009years, with bipolar depression, receiving mood\u2010stabilizing medications, were studied. Antidepressants were discontinued for at least 7\u2009days before single intravenous ketamine infusion (0.5\u2009mg\/kg body weight). Response to ketamine was defined as \u226550% reduction on 17\u2010item Hamilton Depression Rating Scale (HDRS) after 1\u2009week, and remission as HDRS score \u22647. Serum BDNF, NGF, NTF3, NTF4 and GDNF levels were estimated by enzyme\u2010linked immunosorbent assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 13 ketamine responders and 12 non\u2010responders. The remission was obtained in eight and 12 patients after seven and 14\u2009days, respectively. At baseline, there were no differences between responders and non\u2010responders in any of the neurotrophins. Serum BDNF was significantly reduced after 7\u2009days in non\u2010responders. Serum NGF, NT3, NT4 and GDNF did not significantly change.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results confirm an antidepressant effect of ketamine infusion as an add\u2010on to mood\u2010stabilizing drugs in bipolar depression resistant to antidepressant treatment. They may also suggest a possible involvement of BDNF in this effect. Copyright \u00a9 2012 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2271","type":"journal-article","created":{"date-parts":[[2012,11,5]],"date-time":"2012-11-05T09:58:16Z","timestamp":1352109496000},"page":"87-90","source":"Crossref","is-referenced-by-count":75,"title":["Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?"],"prefix":"10.1002","volume":"28","author":[{"given":"Janusz K.","family":"Rybakowski","sequence":"first","affiliation":[{"name":"Department of Adult Psychiatry Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Permoda\u2010Osip","sequence":"additional","affiliation":[{"name":"Department of Adult Psychiatry Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Skibinska","sequence":"additional","affiliation":[{"name":"Psychiatric Genetics Unit Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Adamski","sequence":"additional","affiliation":[{"name":"Department of Adult Psychiatry Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Bartkowska\u2010Sniatkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Anaesthesiology and Intensive Therapy Poznan University of Medical Sciences  Poznan Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,11,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10130"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q371"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2011.02.054"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.90"},{"key":"e_1_2_6_6_1","volume-title":"Structured Clinical Interview for DSM\u2010IV Axis I Disorders, Clinician Version (SCID\u2010CV)","author":"First MB","year":"1996"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2007.07.027"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.01.004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.08.015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04659"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2010.98"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(11)70692-7"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.04.029"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1017\/S146114570700795X"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000404"},{"key":"e_1_2_6_16_1","first-page":"683","article-title":"Increase of plasma brain\u2010derived neurotrophic factor levels in two psychotic depressed patients responding to lithium addition to paroxetine treatment","volume":"3","author":"Yoshimura R","year":"2007","journal-title":"Neuropsychiatr Dis Treatm"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(10)70516-2"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1257"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.12.010"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2271","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T16:16:58Z","timestamp":1696868218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/hup.2271"],"URL":"https:\/\/doi.org\/10.1002\/hup.2271","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,5]]}}}